Iovance Biotherapeutics reported early clinical trial data for lifileucel in advanced soft tissue sarcomas, showing promising efficacy signals. The company also received FDA Fast Track designation for ...

Independent Data Monitoring Committee Recommends Discontinuation of Phase III Trial Following Futility AnalysisSYDNEY, AUSTRALIA, March 13, 2026 ...

Immutep's ASX-listed stock fell more than 88% on the news that its phase 3 trial TACTI-004 of LAG-3 inhibitor eftilagimod alfa (efti) as a first-line treatment for non-small cell lung cancer (NSCLC) ...

Independent Data Monitoring Committee Recommends Discontinuation of Phase III Trial Following Futility Analysis SYDNEY, AUSTRALIA, March 13, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: ...

Barclays 28th Annual Global Healthcare Conference March 11, 2026 9:30 AM EDTCompany ParticipantsSara Pellegrino ...

The "Checkpoint Inhibitor Refractory Cancer Drugs Market -- Growth, Share, Opportunities & Competitive Analysis, 2025 -- 2032" report has been added to the Credence Research Inc. offering. The global ...

Finnish biotech launches fully committed rights issue to advance bexmarilimab in rare bone marrow condition and five investigator-led cancer studies Faron Pharmaceuticals Limited (AIM:FARN), the AIM ...

Equity-Insider.com News Commentary -- The five-year cancer survival rate in the United States has reached a record 70%, reflecting decades of progress in early detection, targeted therapy, and ...

An ASX biotech formerly worth over $500 million has lost most of its value after its drug failed to treat lung cancer ...

Immutep Limited IMMP shares are tumbling on Friday following the company’s update for the TACTI-004 Phase 3 trial. The Australia-based biotech announced that the Independent Data Monitoring Committee ...

News, features, and commentary about cancer-related issues ...